| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | 44.07B | 332.92 | 142.88 | 65.19% | 8.45% | 39.76% | 1.06% | 3.76 |
| SLXNWSilexion Therapeutics Ltd. | 63.6M | 0.03 | 0.00 | -132.54% | ||||
| EDITEditas Medicine, Inc. | 205.18M | 2.20 | -0.76 | -58.64% | -430.84% | -14.85% | 0.26 | |
| SGMOSangamo Therapeutics, Inc. | 92.01M | 0.43 | -0.88 | -67.2% | -331.28% | -17.44% | 1.34 | |
| CAMPCAMP4 Therapeutics Corporation | 210.49M | 4.49 | -1.69 | 86.29% | -14.04% | -133.54% | 0.14 | |
| SLNSilence Therapeutics plc | 256.95M | 5.44 | -1.71 | 70.47% | -252.16% | -84.61% | 0.00 | |
| PEPGPepGen Inc. | 202.89M | 6.22 | -2.18 | -57.35% | 0.16 | |||
| ARCTArcturus Therapeutics Holdings Inc. | 224.14M | 8.23 | -2.74 | -12.27% | -72.48% | -29.71% | 0.12 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 5.21M | 0 | 0 | 0 | 2.98M |
| Revenue Growth % | - | - | -100% | - | - | - |
| Cost of Goods Sold | 2.76M | 2.98M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 57.2% | - | - | - | - |
| Gross Profit | -2.76M | 2.23M | 0 | 0 | 0 | 2.98M |
| Gross Margin % | - | 42.8% | - | - | - | 100% |
| Gross Profit Growth % | - | 180.8% | -100% | - | - | - |
| Operating Expenses | 2.17M | 3.16M | 84.47M | 116.54M | 204.79M | 205.45M |
| OpEx % of Revenue | - | 60.69% | - | - | - | 6887.36% |
| Selling, General & Admin | 1.25M | 3.16M | 13.92M | 29.82M | 43.39M | 50.16M |
| SG&A % of Revenue | - | 60.69% | - | - | - | 1681.56% |
| Research & Development | 920K | 2.98M | 70.55M | 86.72M | 147.91M | 155.29M |
| R&D % of Revenue | - | 57.2% | - | - | - | 5205.8% |
| Other Operating Expenses | 0 | -2.98M | 0 | 0 | 13.5M | 0 |
| Operating Income | -2.17M | -932K | -84.47M | -116.54M | -204.79M | -202.47M |
| Operating Margin % | - | -17.89% | - | - | - | -6787.36% |
| Operating Income Growth % | - | 57.09% | -8963.73% | -37.96% | -75.72% | 1.14% |
| EBITDA | 4.34M | -889K | -83.91M | -114.32M | -200.14M | -196.34M |
| EBITDA Margin % | - | -17.06% | - | - | - | -6581.93% |
| EBITDA Growth % | - | -120.47% | -9338.25% | -36.25% | -75.07% | 1.9% |
| D&A (Non-Cash Add-back) | 6.52M | 43K | 568K | 2.22M | 4.65M | 6.13M |
| EBIT | -2.52M | -932K | -84.47M | -116.54M | -191.29M | -202.47M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 3.52M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 3.52M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | -611K | -81.38M | -6.22M | 6.38M | 6.58M |
| Pretax Income | -2.52M | -1.54M | -165.85M | -122.77M | -198.41M | -195.88M |
| Pretax Margin % | - | -29.62% | - | - | - | -6566.61% |
| Income Tax | 4K | 1.87M | -486K | -948K | -279K | 0 |
| Effective Tax Rate % | 100.16% | 221% | 99.71% | 99.23% | 99.86% | 100% |
| Net Income | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M |
| Net Margin % | - | -65.45% | - | - | - | -6566.61% |
| Net Income Growth % | - | -34.84% | -4749.47% | 26.33% | -62.64% | 1.14% |
| Net Income (Continuing) | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03 | -0.05 | -1.92 | -1.46 | -2.18 | -1.65 |
| EPS Growth % | - | -80.82% | -3542.61% | 24.04% | -49.09% | 24.17% |
| EPS (Basic) | -0.03 | -0.05 | -1.92 | -1.46 | -2.18 | -1.65 |
| Diluted Shares Outstanding | 95.73M | 95.73M | 95.73M | 97.21M | 90.97M | 118.6M |
| Basic Shares Outstanding | 95.73M | 95.73M | 95.73M | 97.21M | 90.97M | 118.6M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 8.7M | 53.4M | 270.58M | 296.62M | 142.98M | 211.89M |
| Cash & Short-Term Investments | 8.65M | 53.33M | 269.62M | 293.92M | 121.67M | 190.44M |
| Cash Only | 8.65M | 36.98M | 185.42M | 187.62M | 41.57M | 182.48M |
| Short-Term Investments | 0 | 16.35M | 84.2M | 106.3M | 80.09M | 7.97M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 50K | 0 | 0 | 246K | 2.25M | 14.67M |
| Total Non-Current Assets | 0 | 1.38M | 31.28M | 63.7M | 50.88M | 85.62M |
| Property, Plant & Equipment | 0 | 596K | 15.68M | 48.55M | 36.6M | 71.56M |
| Fixed Asset Turnover | - | 8.74x | - | - | - | 0.04x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 785K | 15.6M | 15.14M | 14.28M | 14.06M |
| Total Assets | 8.7M | 54.78M | 301.86M | 360.31M | 193.85M | 297.51M |
| Asset Turnover | - | 0.10x | - | - | - | 0.01x |
| Asset Growth % | - | 529.91% | 451% | 19.37% | -46.2% | 53.47% |
| Total Current Liabilities | 7.31M | 19.44M | 57.98M | 26.71M | 56.42M | 37.96M |
| Accounts Payable | 0 | 250K | 1.44M | 4.33M | 19.54M | 11.35M |
| Days Payables Outstanding | - | 30.62 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 7.09M |
| Other Current Liabilities | 7.31M | 19.08M | 14.66M | 6.98M | 10.91M | 6.93M |
| Current Ratio | 1.19x | 2.75x | 4.67x | 11.10x | 2.53x | 5.58x |
| Quick Ratio | 1.19x | 2.75x | 4.67x | 11.10x | 2.53x | 5.58x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 1.87M | 4.31M | 17.33M | 4.36M | 106.4M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 3.07M | 17.05M | 4.36M | 37.18M |
| Deferred Tax Liabilities | 0 | 1.87M | 1.24M | 279K | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 6M |
| Total Liabilities | 7.31M | 21.31M | 62.3M | 44.04M | 60.78M | 144.36M |
| Total Debt | 0 | 0 | 10.41M | 28.75M | 13.63M | 40.79M |
| Net Debt | -8.65M | -36.98M | -175.01M | -158.88M | -27.94M | -141.68M |
| Debt / Equity | - | - | 0.04x | 0.09x | 0.10x | 0.27x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.99x | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 1.39M | 33.47M | 239.56M | 316.27M | 133.07M | 153.15M |
| Equity Growth % | - | 2309.94% | 615.66% | 32.02% | -57.92% | 15.09% |
| Book Value per Share | 0.01 | 0.35 | 2.50 | 3.25 | 1.46 | 1.29 |
| Total Shareholders' Equity | 1.39M | 33.47M | 239.56M | 316.27M | 133.07M | 153.15M |
| Common Stock | 1K | 0 | 0 | 2K | 2K | 2K |
| Retained Earnings | -2.6M | -6.01M | -171.38M | -293.2M | -491.33M | -687.21M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -27K | -384K | -15K | 1K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -1.33M | -5.54M | -34.08M | -131.83M | -165.41M | -122.86M |
| Operating CF Margin % | - | -106.41% | - | - | - | -4118.84% |
| Operating CF Growth % | - | -315.59% | -514.75% | -286.79% | -25.48% | 25.72% |
| Net Income | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M |
| Depreciation & Amortization | 0 | 43K | 568K | 2.22M | 4.65M | 6.13M |
| Stock-Based Compensation | 0 | 391K | 1.75M | 6.46M | 13.91M | 26.07M |
| Deferred Taxes | 0 | 1.87M | -624K | -964K | -279K | 0 |
| Other Non-Cash Items | 703K | -4.6M | 98.42M | 17.68M | 11.79M | 9.74M |
| Working Capital Changes | 492K | 164K | 31.18M | -35.4M | 2.65M | 31.08M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 250K | 1.19M | 2.46M | 9.14M | -5.26M |
| Cash from Investing | 0 | -1.06M | -73.63M | -47.1M | 18.71M | 68.46M |
| Capital Expenditures | 0 | -639K | -4.15M | -16.09M | -8.72M | -7.29M |
| CapEx % of Revenue | - | 12.26% | - | - | - | 244.52% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -423K | -496K | -665K | -170K | 1M |
| Cash from Financing | 9.98M | 34.93M | 269.28M | 181.49M | 655K | 195.88M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 655K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -20K | -1.09M | -3.82M | 0 | 25.74M |
| Net Change in Cash | 0 | 28.33M | 161.57M | 2.57M | -146.05M | 141.47M |
| Free Cash Flow | -1.33M | -6.18M | -38.23M | -147.92M | -174.14M | -130.16M |
| FCF Margin % | - | -118.68% | - | - | - | -4363.36% |
| FCF Growth % | - | -363.49% | -518.34% | -286.91% | -17.72% | 25.25% |
| FCF per Share | -0.01 | -0.06 | -0.40 | -1.52 | -1.91 | -1.10 |
| FCF Conversion (FCF/Net Income) | 0.53x | 1.63x | 0.21x | 1.08x | 0.83x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 141K | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -182.07% | -19.56% | -121.13% | -43.83% | -88.19% | -136.88% |
| Return on Invested Capital (ROIC) | - | - | -207.57% | -78.77% | -117.01% | -260.47% |
| Gross Margin | - | 42.8% | - | - | - | 100% |
| Net Margin | - | -65.45% | - | - | - | -6566.61% |
| Debt / Equity | - | - | 0.04x | 0.09x | 0.10x | 0.27x |
| FCF Conversion | 0.53x | 1.63x | 0.21x | 1.08x | 0.83x | 0.63x |
| Revenue Growth | - | - | -100% | - | - | - |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics